---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-228130"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-09-05T23:59:59+00:00"
generated_at: "2026-06-10T23:52:52.435718+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Travere closes $210M asset sale to Mirum; eligible for up to $235M in milestones

## Summary
- Upfront cash payment of $210M from Mirum for Chenodal and Cholbam assets.
- Potential milestone payments up to $235M based on annual net sales tiers ($125M-$500M).
- Transaction closed on August 31, 2023, as previously announced on July 16, 2023.
- Pro forma financial statements to be filed by amendment within four business days.

## SEC filing metadata
- accession: 0001193125-23-228130
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-09-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/0001193125-23-228130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/d548855d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-228130
- JSON: https://secwatch.observer/filing/0001193125-23-228130.json
- Plain text: https://secwatch.observer/filing/0001193125-23-228130.txt

## Key facts
- M&A Transactions
  Travere Therapeutics, Inc. completed a disposition involving Mirum Pharmaceuticals, Inc. for $210,000,000 (closed 2023-08-31).
  - Action: disposition
  - Counterparty: Mirum Pharmaceuticals, Inc.
  - Consideration: $210,000,000
  - Closing: 2023-08-31
  source text: of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”). In connection with the Closing, Mirum paid the Company an upfront cash payment of $210,000,000. Pursuant to the Purchase Agreement, after the Closing, the Company is eligible to receive up to $235,000,000 upon the achievement of certain milestones based on specified
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000119312523228130/0001193125-23-228130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.